This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through September 7, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
moving-average-crossover: Archive
Should You Buy PTC Inc. (PTC) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
PTCNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
PTC Inc. (PTC) Surges 33.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
PTC Inc. (PTC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
PTCNegative Net Change MANHPositive Net Change
momentum-stocks moving-average-crossover price-performance stock-price-movement stocks-moving-today
Nu (NU) Surges 13.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
Nu (NU) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
NUNegative Net Change WNEBNegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Sendas Distribuidora (ASAIY) Surges 20.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Sendas Distribuidora (ASAIY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ASAIYNegative Net Change WLKPositive Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Schrodinger (SDGR) Surges 7.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Schrodinger (SDGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
SDGRNegative Net Change NYXHNegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Bath & Body Works (BBWI) Surges 8.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Bath & Body Works (BBWI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
BBWIPositive Net Change ARHSPositive Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Emergent Biosolutions (EBS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
EBSNegative Net Change MXCTNegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Grupo Aeroportuario del Pacifico (PAC) Surges 4.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
Grupo Aeroportuario del Pacifico (PAC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
PACNegative Net Change CARPositive Net Change
momentum-stocks moving-average-crossover price-performance stock-price-movement stocks-moving-today
Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength?
by Zacks Equity Research
Genmab (GMAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
GMABNegative Net Change VSTMNegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
NVAXPositive Net Change VRTXNegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today